Clinical Trials
25
Active:1
Completed:3
Trial Phases
4 Phases
Phase 1:2
Phase 2:4
Phase 3:3
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (14 trials with phase data)• Click on a phase to view related trials
Not Applicable
5 (35.7%)Phase 2
4 (28.6%)Phase 3
3 (21.4%)Phase 1
2 (14.3%)Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Not Applicable
Not yet recruiting
- Conditions
- Aggressive Diffuse Large B-cell LymphomaHigh-grade B-cell Lymphoma (HGBL)Follicular Lymphoma (FL) Grade 3B
- Interventions
- Drug: Loncastuximab Tesirine and Epcoritamab
- First Posted Date
- 2025-09-29
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Universität Münster
- Target Recruit Count
- 120
- Registration Number
- NCT07197307
- Locations
- 🇩🇪
Universitätsklinikum Münster, Medizinische Klinik A, Münster, Germany
Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma
Phase 2
Terminated
- Conditions
- B-cell Lymphoma RefractoryB-cell Lymphoma Recurrent
- Interventions
- Procedure: LeukapheresisDrug: Bridging TherapyDrug: LymphodepletionGenetic: Axicabtagene Ciloleucel
- First Posted Date
- 2025-04-04
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Universität Münster
- Target Recruit Count
- 1
- Registration Number
- NCT06912529
- Locations
- 🇩🇪
Medizinische Klinik A Hämatologie, Hämostaseologie, Onkologie und Pneumologie Universitätsklinikum Münster, Münster, Germany
ESGE-Quality Improvement in Endoscopy: ERCP
- Conditions
- Post-ERCP Acute Pancreatitis
- First Posted Date
- 2024-12-11
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Universität Münster
- Target Recruit Count
- 1254
- Registration Number
- NCT06727851
- Locations
- 🇩🇪
University of Muenster, Josephs Hospital Warendorf, Academic Teaching Hospital, Warendorf, Germany
Clinical Trial Evaluating Safety of 5-Aminolevulinic Acid (5-ALA) Combined With CV01 Delivery of Ultrasound for Sonodynamic Therapy (SDT) in Patients With Newly Diagnosed High-Grade Glioma (HGG) Prior to Resection and Standard Adjuvant Therapy (ALA SDT GLIOMA 401)
Phase 1
Recruiting
- Conditions
- Anaplastic Astrocytoma (AA)Anaplastic Oligodendroglioma (AO)Glioblastoma (GBM)
- Interventions
- Drug: 5-Aminolevulinic acid Hydrochloride (Gliolan®)Device: CV01
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Universität Münster
- Target Recruit Count
- 14
- Registration Number
- NCT06665724
- Locations
- 🇩🇪
Department of Neurosurgery, University Hospital Münster, Münster, Germany
Survey on the Evaluation of Medication Information Leaflets for Organ Transplant Patients
Recruiting
- Conditions
- Organ Transplantation
- First Posted Date
- 2024-10-22
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Universität Münster
- Target Recruit Count
- 30
- Registration Number
- NCT06652919
- Locations
- 🇩🇪
Institute of Pharmaceutical and Medicinal Chemistry, Clinical Pharmacy, University of Münster, Münster, Nordrhein-Westfalen, Germany
- Prev
- 1
- 2
- 3
- 4
- 5
- Next
News
No news found